UBT251 vs Pemvidutide

Head-to-head comparison of UBT251 (UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyUBT251Pemvidutide
CategoryWeight ManagementWeight Management
Full NameUBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonistPemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist
Molecular WeightN/AN/A
Half-LifeApproximately 1 weekApproximately 1 week
Amino AcidsN/AN/A
Typical DoseInvestigational; no established human doseTrial-dependent; once-weekly SC titration
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count818
Research StatusPre-clinicalClinical

UBT251 Benefits

  • weight reduction
  • improved satiety
  • enhanced energy expenditure
  • better insulin sensitivity

Pemvidutide Benefits

  • appetite suppression
  • body-weight reduction
  • improved liver-fat markers
  • better glycemic control

UBT251 Dosing

once-weekly subcutaneous injection|dose escalation in studies|maintenance after tolerability assessment

Pemvidutide Dosing

once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose

UBT251 Side Effects

  • nausea
  • diarrhea
  • fatigue

Pemvidutide Side Effects

  • nausea
  • vomiting
  • diarrhea

Research Overview

UBT251

Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.

Pemvidutide

Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

UBT251 stacks with:

metforminorlistat

Pemvidutide stacks with:

metformintopiramate
glp1gipglucagontriagonistweight-managementdual-agonistobesitymash